Converge Bio Secures $25 Million to Advance AI-Driven Drug Discovery with Support from Tech Industry Leaders
Converge Bio, a startup specializing in artificial intelligence for drug discovery, has raised $25 million in a Series A funding round led by Bessemer Venture Partners. The round also attracted investment from executives affiliated with Meta, OpenAI, and Wiz, highlighting growing interest in AI applications within healthcare.
